Company news

Intensity Therapeutics, Inc. news in 2024

Intensity Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast C...

December 11, 2024

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

November 20, 2024

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (...

November 17, 2024

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 12, 2024

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

November 7, 2024

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

October 30, 2024

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 7, 2024

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

July 8, 2024

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 14, 2024

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

April 1, 2024

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

March 13, 2024

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

March 13, 2024

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

February 20, 2024

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

January 2, 2024

Decks in 2024